MIOKARD SHIKASTLANISHINING PATOBIOKIMYOVIY ASOSLARI VA DO‘LANA (CRATAEGUS SPP.) EKSTRAKTLARINING KARDIOPROTEKTIV SALOHIYATI: ILMIY ADABIYOTLAR SHARHI
- Authors
-
-
Axmatova Shaxzodabonu Olimovna
¹ ZARMED universiteti, Davolash ishi yo‘nalishi talabasi,
Author
-
Raxmonov Farxod Xolbayevich²
² ZARMED universiteti, Tibbiy va biologik kimyo kafedrasi,
Author
-
- Keywords:
- Array
- Abstract
-
Maqsad. Miokard ishemiyasi va reperfuziya shikastlanishining molekulyar asoslarini tahlil qilish hamda do‘lana (Crataegus spp.) preparatlarining yurak-qon tomir tizimiga ta’siri bo‘yicha eksperimental va klinik dalillarni qiyosiy baholash. Materiallar va usullar. PubMed indeksida mavjud original tadqiqotlar, randomizatsiyalangan klinik sinovlar, meta-tahlillar va sharhlar asosida narrativ adabiyotlar tahlili o‘tkazildi. Natijalar. Miokardda ishemiya ATF tanqisligi, ion gomeostazining buzilishi va hujayraviy atsidoz bilan kechadi; reperfuziyada reaktiv kislorod shakllari, kalsiy ortiqchaligi va mitoxondrial permeabilitet o‘zgarishlari shikastlanishni chuqurlashtiradi. Do‘lana polifenollari uchun antioksidant, endoteliyga bog‘liq vazorelaksatsiya va antiapoptotik ta’sirlar asosan eksperimental tizimlarda qayd etilgan. Kichik klinik sinovlar ayrim simptomatik ko‘rsatkichlar yaxshilanishini ko‘rsatgan bo‘lsa-da, yirik tadqiqotlar yurak hodisalari hamda funksional natijalar bo‘yicha izchil ustunlikni tasdiqlamagan. Xulosa. Do‘lana ekstraktlari istiqbolli fitokimyoviy tadqiqot obyekti, biroq miokard infarkti yoki yurak yetishmovchiligida dalillarga asoslangan standart muolajaning o‘rnini bosa olmaydi.
- References
-
1.Yellon D. M., Hausenloy D. J. Myocardial reperfusion injury // New England Journal of Medicine. 2007. Vol. 357, № 11. P. 1121–1135. DOI: 10.1056/NEJMra071667.
2.Hausenloy D. J., Yellon D. M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target // Journal of Clinical Investigation. 2013. Vol. 123, № 1. P. 92–100. DOI: 10.1172/JCI62874.
3.Gunata M., Parlakpinar H. A review of myocardial ischaemia/reperfusion injury: Pathophysiology, experimental models, biomarkers, genetics and pharmacological treatment // Cell Biochemistry and Function. 2021. Vol. 39, № 2. P. 190–217. DOI: 10.1002/cbf.3587.
4.Tassell M. C., Kingston R., Gilroy D., Lehane M., Furey A. Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease // Pharmacognosy Reviews. 2010. Vol. 4, № 7. P. 32–41. DOI: 10.4103/0973-7847.65324.
5.Li R., Luan F., Zhao Y. et al. Crataegus pinnatifida: A botanical, ethnopharmacological, phytochemical, and pharmacological overview // Journal of Ethnopharmacology. 2023. Vol. 301. Art. 115819. DOI: 10.1016/j.jep.2022.115819.
6.Zhang S.-Y., Sun X.-L., Yang X.-L. et al. Botany, traditional uses, phytochemistry and pharmacological activity of Crataegus pinnatifida (Chinese hawthorn): a review // Journal of Pharmacy and Pharmacology. 2022. Vol. 74, № 11. P. 1507–1545. DOI: 10.1093/jpp/rgac050.
7.Brixius K., Willms S., Napp A. et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177 // Cardiovascular Drugs and Therapy. 2006. Vol. 20, № 3. P. 177–184. DOI: 10.1007/s10557-006-8723-7.
8.Anselm E., Socorro V. F. M., Dal-Ros S. et al. Crataegus special extract WS 1442 causes endothelium-dependent relaxation via a redox-sensitive Src- and Akt-dependent activation of endothelial NO synthase but not via activation of estrogen receptors // Journal of Cardiovascular Pharmacology. 2009. Vol. 53, № 3. P. 253–260. DOI: 10.1097/FJC.0b013e31819ccfc9.
9.Cheng F. et al. Ethanol Extract of Chinese Hawthorn (Crataegus pinnatifida) Fruit Reduces Inflammation and Oxidative Stress in Rats with Doxorubicin-Induced Chronic Heart Failure // Medical Science Monitor. 2020. Art. e926654. DOI: 10.12659/MSM.926654.
10.Jayachandran K. S., Khan M., Selvendiran K., Devaraj S. N., Kuppusamy P. Crataegus oxycantha extract attenuates apoptotic incidence in myocardial ischemia-reperfusion injury by regulating Akt and HIF-1 signaling pathways // Journal of Cardiovascular Pharmacology. 2010. Vol. 56, № 5. P. 526–531. DOI: 10.1097/FJC.0b013e3181f64c51.
11.Pittler M. H., Guo R., Ernst E. Hawthorn extract for treating chronic heart failure // Cochrane Database of Systematic Reviews. 2008. № 1. Art. CD005312. DOI: 10.1002/14651858.CD005312.pub2.
12.Holubarsch C. J. F., Colucci W. S., Meinertz T., Gaus W., Tendera M. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial // European Journal of Heart Failure. 2008. Vol. 10, № 12. P. 1255–1263. DOI: 10.1016/j.ejheart.2008.10.004.
13.Zick S. M., Vautaw B. M., Gillespie B., Aaronson K. D. Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial // European Journal of Heart Failure. 2009. Vol. 11, № 10. P. 990–999. DOI: 10.1093/eurjhf/hfp116.
14.Walker A. F., Marakis G., Simpson E. et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial // British Journal of General Practice. 2006. Vol. 56, № 527. P. 437–443. PMID: 16762125.
15.Tankanow R., Tamer H. R., Streetman D. S. et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha) // Journal of Clinical Pharmacology. 2003. Vol. 43, № 6. P. 637–642. PMID: 12817526.
16.Kydyrbayeva A., Shalakhmetova T., Smalinskiene A. et al. Crataegus Species as a Source of Geroprotective Phytochemicals: Biological Activities, Molecular Mechanisms and Therapeutic Perspectives // Life. 2026. Vol. 16, № 9. Art. 1478. DOI: 10.3390/life16091478.
17.Hausenloy D. J., Chilian W., Crea F. et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection // Cardiovascular Research. 2019. Vol. 115, № 7. P. 1143–1155. DOI: 10.1093/cvr/cvy286.
18.Davidson S. M., Ferdinandy P., Andreadou I. et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week // Journal of the American College of Cardiology. 2019. Vol. 73, № 1. P. 89–99. DOI: 10.1016/j.jacc.2018.09.086.
1.Yellon D. M., Hausenloy D. J. Myocardial reperfusion injury // New England Journal of Medicine. 2007. Vol. 357, № 11. P. 1121–1135. DOI: 10.1056/NEJMra071667.
2.Hausenloy D. J., Yellon D. M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target // Journal of Clinical Investigation. 2013. Vol. 123, № 1. P. 92–100. DOI: 10.1172/JCI62874.
3.Gunata M., Parlakpinar H. A review of myocardial ischaemia/reperfusion injury: Pathophysiology, experimental models, biomarkers, genetics and pharmacological treatment // Cell Biochemistry and Function. 2021. Vol. 39, № 2. P. 190–217. DOI: 10.1002/cbf.3587.
4.Tassell M. C., Kingston R., Gilroy D., Lehane M., Furey A. Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease // Pharmacognosy Reviews. 2010. Vol. 4, № 7. P. 32–41. DOI: 10.4103/0973-7847.65324.
5.Li R., Luan F., Zhao Y. et al. Crataegus pinnatifida: A botanical, ethnopharmacological, phytochemical, and pharmacological overview // Journal of Ethnopharmacology. 2023. Vol. 301. Art. 115819. DOI: 10.1016/j.jep.2022.115819.
6.Zhang S.-Y., Sun X.-L., Yang X.-L. et al. Botany, traditional uses, phytochemistry and pharmacological activity of Crataegus pinnatifida (Chinese hawthorn): a review // Journal of Pharmacy and Pharmacology. 2022. Vol. 74, № 11. P. 1507–1545. DOI: 10.1093/jpp/rgac050.
7.Brixius K., Willms S., Napp A. et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177 // Cardiovascular Drugs and Therapy. 2006. Vol. 20, № 3. P. 177–184. DOI: 10.1007/s10557-006-8723-7.
8.Anselm E., Socorro V. F. M., Dal-Ros S. et al. Crataegus special extract WS 1442 causes endothelium-dependent relaxation via a redox-sensitive Src- and Akt-dependent activation of endothelial NO synthase but not via activation of estrogen receptors // Journal of Cardiovascular Pharmacology. 2009. Vol. 53, № 3. P. 253–260. DOI: 10.1097/FJC.0b013e31819ccfc9.
9.Cheng F. et al. Ethanol Extract of Chinese Hawthorn (Crataegus pinnatifida) Fruit Reduces Inflammation and Oxidative Stress in Rats with Doxorubicin-Induced Chronic Heart Failure // Medical Science Monitor. 2020. Art. e926654. DOI: 10.12659/MSM.926654.
10.Jayachandran K. S., Khan M., Selvendiran K., Devaraj S. N., Kuppusamy P. Crataegus oxycantha extract attenuates apoptotic incidence in myocardial ischemia-reperfusion injury by regulating Akt and HIF-1 signaling pathways // Journal of Cardiovascular Pharmacology. 2010. Vol. 56, № 5. P. 526–531. DOI: 10.1097/FJC.0b013e3181f64c51.
11.Pittler M. H., Guo R., Ernst E. Hawthorn extract for treating chronic heart failure // Cochrane Database of Systematic Reviews. 2008. № 1. Art. CD005312. DOI: 10.1002/14651858.CD005312.pub2.
12.Holubarsch C. J. F., Colucci W. S., Meinertz T., Gaus W., Tendera M. The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial // European Journal of Heart Failure. 2008. Vol. 10, № 12. P. 1255–1263. DOI: 10.1016/j.ejheart.2008.10.004.
13.Zick S. M., Vautaw B. M., Gillespie B., Aaronson K. D. Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial // European Journal of Heart Failure. 2009. Vol. 11, № 10. P. 990–999. DOI: 10.1093/eurjhf/hfp116.
14.Walker A. F., Marakis G., Simpson E. et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial // British Journal of General Practice. 2006. Vol. 56, № 527. P. 437–443. PMID: 16762125.
15.Tankanow R., Tamer H. R., Streetman D. S. et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha) // Journal of Clinical Pharmacology. 2003. Vol. 43, № 6. P. 637–642. PMID: 12817526.
16.Kydyrbayeva A., Shalakhmetova T., Smalinskiene A. et al. Crataegus Species as a Source of Geroprotective Phytochemicals: Biological Activities, Molecular Mechanisms and Therapeutic Perspectives // Life. 2026. Vol. 16, № 9. Art. 1478. DOI: 10.3390/life16091478.
17.Hausenloy D. J., Chilian W., Crea F. et al. The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection // Cardiovascular Research. 2019. Vol. 115, № 7. P. 1143–1155. DOI: 10.1093/cvr/cvy286.
18.Davidson S. M., Ferdinandy P., Andreadou I. et al. Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week // Journal of the American College of Cardiology. 2019. Vol. 73, № 1. P. 89–99. DOI: 10.1016/j.jacc.2018.09.086.
- Downloads
- Published
- 2026-11-13
- Section
- Articles